Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in c...

FDA Recall #D-0322-2024 — Class III — January 25, 2024

Recall #D-0322-2024 Date: January 25, 2024 Classification: Class III Status: Ongoing

Product Description

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58

Reason for Recall

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Recalling Firm

Teva Pharmaceuticals USA, Inc — Parsippany, NJ

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

19,824 cartons

Distribution

nationwide

Code Information

Lot #: 100040731, Exp 7/31/2024

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated